Selective knockout of the vitamin d receptor in the heart results in cardiac hypertrophy: Is the heart a drugable target for vitamin d receptor agonists?

Circulation

Volumn 124, Issue 17, 2011, Pages 1808-1810

  Simpson, Robert U ^a  

^a 1150 West Medical Center Drive ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ATRIAL NATRIURETIC FACTOR; CALCINEURIN; CALCITRIOL; CARD 024; CYTOCHROME P450; MATRIX METALLOPROTEINASE; MESSENGER RNA; PARATHYROID HORMONE; PARICALCITOL; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

CALCIUM BLOOD LEVEL; CARDIOVASCULAR FUNCTION; DISEASE MODEL; EXTRACELLULAR MATRIX; FIBROBLAST; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; OSTEOMALACIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; VITAMIN D DEFICIENCY;

ANIMALS; CARDIOMEGALY; GENE DELETION; MYOCYTES, CARDIAC; RECEPTORS, CALCITRIOL;

EID: 80054978632     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.061234     Document Type: Review

References (21)

1. Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011;124: 1838-1847.
2. Weishaar RE, Kim SN, Saunders DE, Simpson RU. Involvement of vitamin D3 with cardiovascular function III. Effects on physical and morphological properties. Am J Physiol. 1990;258:E134-E142. (Pubitemid 20068590)
3. Weishaar RE, Simpson RU. Vitamin D. and cardiovascular function in rats. J Clin Invest. 1987;79:1706-1711.
4. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function II. Direct and indirect effects. Am J Physiol Endocrinol Metab. 1987;253:E675-E683.
5. Simpson RU, Thomas GA, Arnold AJ. Identification of 1,25 dihydroxyvitamin D3 receptors and activities in muscle. J. Biol. Chem. 1985; 260:8882-889l.
6. O'Connell TD, Simpson RU. Immunochemical identification of the 1,25- dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int. 1996;20:621-624. (Pubitemid 26397498)
7. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229-238. (Pubitemid 34787360)
8. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288:E125-E132. (Pubitemid 40023798)
9. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium independent and 1,25(OH)2D3-dependent regulation of the renin angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74:170-179. (Pubitemid 351915078)
10. Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2007;103:416-419. (Pubitemid 46415673)
11. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000;15:264-272. (Pubitemid 30496722)
12. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104:16810-16815. (Pubitemid 350210947)
13. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol. 2008;51:559-564.
14. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383-392. (Pubitemid 29353135)
15. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179-184. (Pubitemid 38072630)
16. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115-1125. (Pubitemid 41710323)
17. Gafter U, Battler A, Eldar M, Zevin D, Neufeld HN, Levi J. Effect of hyperparathyroidism on cardiac function in patients with end-stage renal disease. Nephron. 1985;41:30-33. (Pubitemid 15006029)
18. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
19. Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol. 2009;158:395-412.
20. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, Erwin PJ, Hensrud DD, Murad MH, Montori VM. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96:1931-1942.
21. Nemerovski CW, Dorsch MP, Simpson RU, Bone HG, Aaronson KD, Bleske BE. Vitamin D and cardiovascular disease. Pharmacotherapy. 2009;29:691-708.